Key facts
- This page summarizes Sofinnova Partners SAS's Form 4 filing for CinCor Pharma, Inc..
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2022, 15:36.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Conversion of derivative security
Purchase
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Conversion of derivative security
Conversion of derivative security
Additional SEC filing notes
Footnote F1
Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
Footnote F2
The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.